ClawHub

Bristol Myers Squibb

v1.0.0

Global biopharma leader specializing in immuno-oncology and cardiovascular drugs, maker of Opdivo and Eliquis with $45B revenue in 2024.

⭐ 0· 89·0 current·0 all-time
by@hanxueyuan

Install

OpenClaw Prompt Flow

Install with OpenClaw

Best for remote or guided setup. Copy the exact prompt, then paste it into OpenClaw for hanxueyuan/bristol-myers-squibb.

Previewing Install & Setup.
Prompt PreviewInstall & Setup
Install the skill "Bristol Myers Squibb" (hanxueyuan/bristol-myers-squibb) from ClawHub.
Skill page: https://clawhub.ai/hanxueyuan/bristol-myers-squibb
Keep the work scoped to this skill only.
After install, inspect the skill metadata and help me finish setup.
Use only the metadata you can verify from ClawHub; do not invent missing requirements.
Ask before making any broader environment changes.

Command Line

CLI Commands

Use the direct CLI path if you want to install manually and keep every step visible.

OpenClaw CLI

Bare skill slug

openclaw skills install bristol-myers-squibb

ClawHub CLI

Package manager switcher

npx clawhub@latest install bristol-myers-squibb
Security Scan
VirusTotalVirusTotal
Benign
View report →
OpenClawOpenClaw
Benign
high confidence
✓
Purpose & Capability
Name, description, and SKILL.md content are consistent: the skill provides a company overview, timeline, business model and facts about Bristol-Myers Squibb. There are no unrelated requirements (no binaries, env vars, or config paths).
✓
Instruction Scope
SKILL.md contains static content and a short read_when trigger list; it does not instruct the agent to read files, access environment variables, call external endpoints, or transmit data. Scope is limited to presenting corporate information.
✓
Install Mechanism
No install spec and no code files — nothing is written to disk or downloaded. Lowest-risk installation model (instruction-only).
✓
Credentials
The skill requires no environment variables, credentials, or config paths. Requested privileges are proportional (in fact, none are requested).
✓
Persistence & Privilege
always is false and the skill is user-invocable. It does not request persistent presence or modify other skills or system settings.
Assessment
This skill is a static company profile and appears safe to install from a technical-permission perspective because it asks for no credentials and performs no installs. However, it contains factual statements without cited sources and may be out of date; do not rely on it for financial or clinical decisions without verifying facts against authoritative sources. If you prefer explicit provenance, ask the publisher for citation links or prefer skills that fetch live data from reputable APIs.

Like a lobster shell, security has layers — review code before you run it.

latestvk9748zvc2v6nqkmm5bshkw471s85a5zm
89downloads
0stars
1versions
Updated 5d ago
v1.0.0
MIT-0
@hanxueyuan
latest
Download

历史时间线

  • 1887年：Bristol-Myers公司在纽约成立
  • 1989年：Bristol-Myers与Squibb合并成立BMS
  • 2009年：收购Medarex获得PD-1抑制剂Opdivo技术
  • 2019年：740亿美元收购Celgene（史上最大医药并购之一）
  • 2024年：Opdivo年销售额超80亿美元，Eliquis全球最畅销药物之一

商业模式

聚焦肿瘤学（占收入约60%）、血液学和免疫学、心血管。通过大型并购获取明星药物（Opdivo、Eliquis、Revlimid），同时投资细胞疗法和基因编辑等前沿技术平台。

护城河分析

PD-1免疫疗法的先发优势（Opdivo）、与默沙东的联合用药竞争推动市场扩大、Celgene整合带来的血液学管线、与Ono Pharmaceutical在日本市场的独家合作

关键数据

2024年营收约450亿美元，研发支出约95亿美元，全球员工约34,000人

有趣事实

  • Opdivo（纳武利尤单抗）是全球首个获批的PD-1抑制剂，开创了癌症免疫治疗新时代
  • Eliquis在全球抗凝血药物市场的份额超过40%，年销售额突破200亿美元

Comments

Loading comments...